Lymph node ratio (LNR) as a complementary staging system to TNM staging in salivary gland cancer
ConclusionsLNR classification should be considered as a complementary system to TNM staging and LNR classification based clinical trials deserve further research.
Conclusions: PBT should be strongly considered when ipsilateral radiation therapy is indicated for major salivary gland cancer based on a considerably lower incidence of acute grade 2 or higher toxicity in this analysis compared to historical IMRT outcomes. PMID: 31805791 [PubMed - as supplied by publisher]
CONCLUSION: This combination demonstrated activity in HN, with fewer responses in SGC. Toxicities were higher than reported with pembrolizumab alone. PMID: 31796519 [PubMed - as supplied by publisher]
CONCLUSION: A favorable response of HER2-positive salivary gland carcinomas to an antibody-drug conjugate could be shown. Furthermore, no convincing data regarding response to programmed cell death protein 1 (PD1)/programmed death ligand 1 (PD-L1) inhibitors in advanced salivary gland cancer were presented. Further studies and ideas for new treatment approaches will be needed to improve the therapeutic options for patients with salivary gland carcinoma. PMID: 31628530 [PubMed - as supplied by publisher]
Salivary gland cancer (SGC) is a distinct but heterogeneous group of malignancies comprising approximately 6.5% of cases within head and neck cancer . This makes it a rare cancer, with an estimated age-standardized annual incidence of less than 2/100.000 in most countries . The most recent World Health Organization classification of Head and Neck Tumours distinguishes 22 histopathological subtypes of SGC, which makes each subtype even rarer . Recognition of, and differentiation between these different subtypes is notoriously difficult and different subtypes exhibit different clinical features adding up to the comp...
ConclusionsWe are the first that have successfully developed and characterized long-term organoid cultures for ACC and SDC. These organoid cell lines will facilitate pre-clinical and pharmacological studies. Other SGC organoid cultures do not grow infinitely, but do provide an in vitro model to study different treatments during initial growth.Legal entity responsible for the studyRadboud University Medical Center.FundingDutch Salivary Gland Cancer Patient Platform.DisclosureAll authors have declared no conflicts of interest.
In conclusion, our data showed that pan-Trk IHC is a reasonable screening test for diagnosing secretory carcinoma of the salivary gland.
In this study, we added 11 years of follow-up (1958-2009), used improved radiation dose estimates, considered effects of smoking and alcohol consumption and performed dose-response analyses by anatomical sub-site. In examining 52 years'worth of data, we ascertained the occurrence of 394 oral cavity/pharyngeal cancers, 486 esophageal cancers and 5,661 stomach cancers among 105,444 subjects. The radiation risk for oral cavity/pharyngeal cancer, other than salivary gland, was elevated but not significantly so. In contrast, salivary gland cancer exhibited a strong linear dose response with excess relative risk (ERR) of 2.54 pe...
Myoepithelial carcinoma (MEC) is an extremely rare salivary gland malignancy accounting for 1% of all salivary gland cancers [1 –4]. MEC has long been reported as a low grade malignancy with indolent clinical behaviour and good long-term survival . These tumours have been reported to arise from a number of organs viz. major and minor salivary gland, breast, airway, etc [1,6,7]. Irrespective of sub-site, surgical resecti on is considered as corner stone of therapy. Even after surgical resection recurrence has been reported, and this highlights an aggressive group of MEC and a plausible benefit of adjuvant therapy.
Abstract Although salivary gland cancers comprise only ∼3-6% of head and neck cancers, treatment options for patients with advanced-stage disease are limited. Because of their rarity, salivary gland malignancies are understudied compared to other exocrine tissue cancers. The comparative lack of progress in this cancer field is particularly evident when it comes to our incomplete understanding of the key molecular signals that are causal for the development and/or progression of salivary gland cancers. Using a novel conditional transgenic mouse (K5:RANKL), we demonstrate that Receptor Activator of NFkB Ligand (...
Conclusions: TLG on restaging FDG-PET predicted PFS and OS in patients with RSGC; patients with predicted poor outcome may benefit from alternate, escalated treatment strategies. Multivariate analysis of clinicopathological and imaging parametersParameterPFS HR (95.0% CI)PFS p-valueOS HR (95.0% CI)OS p-valueHistologic subtype, Adenocarcinoma vs. Non-adenocarcinoma2.27 (1.33- 3.89)0.0031.60 (0.91-2.80)0.09TMTV1.01 (0.99-1.012)0.081.00 (1.00-1.011)0.14TLG1.00 (1.00-1.001)